April 3, 2023
April 3, 2023
On April 3, 2023, the results of the Cell and Gene Therapy (CGT)Asia Innovation Summit were officially announced. Lion TCR, a biotechnology company, was awarded the "Outstanding Innovative Award" for 2023.
The third annual CGT Asia 2023 Innovation Summit, organized by Taas Labs, was held in Shanghai on April 3-4, 2023. More than 200 global cell and gene therapy companies, alongside 1,500 attendees from China and abroad, participated to discuss industry prospects and collaboration opportunities. The conference focused on core topics such as the commercialization of cell therapy products, progress in the development of stem cell therapy drugs, smart technology support for commercialization pathways, medical insurance programs enabling listings of cell therapies, the latest hot topics and innovative research in gene therapy, drug development optimization and delivery technology, strengthening R&D transformation from the laboratory to the clinic, and the development of rare disease gene therapy drugs. The conference aimed to promote technological innovation and integration development of cell gene therapy research and industry and strived to provide a fruitful networking platform for its participants.
Dr. Tina Wang, Chief Medical Officer (CMO) and Chief Operating Officer (COO) of Lion TCR, was also invited to give a keynote speech. She introduced Lion TCR's TCR T cell therapy targeting hepatitis B virus antigens, using mRNA encoding technology and the companies’ clinical experiences with immunotherapy. Dr Wang also stressed Lion TCR’s commitment to continued innovation to benefit patients.
Asa biotechnology company focusing on cell therapy, Lion TCR is committed to pushing the frontiers of novel yet effective and safe immunotherapies. To this end, its use of mRNA encoding TCR in clinical trials for liver cancer treatment has shown good safety and significant efficacy. Through its TCR discovery platform, Lion TCR has discovered several novel targets suitable for different indications, which would be critical towards answering currently unmet clinical needs. The company relentlessly innovates in order to provide patients with more personalized, effective, and safe treatment options, in the process continuously pushing the boundaries of the immunotherapy industry's development.
In this nomination for the CGT Asia Innovation Summit, Lion TCR stood out and won the "Outstanding Innovative Award” for the year 2023, which is testament to its excellence in technological innovation, cutting edge research and development capabilities, and sound clinical strategy being recognised by the industry.
Moving forward, Lion TCR shall continue to tirelessly innovate and strengthen its technological capabilities in order to accelerate the development of new immunotherapies and answer to the many currently unmet clinical needs. Lion TCR will do its utmost to contribute to the healthy development of the industry.
About Lion TCR:
Lion TCR is a clinical-stage biotechnology company focused on TCR-based cell therapy. It is a pioneer in the direct use of mRNA to encode TCRs in immune cells, and has shown good safety and significant efficacy in clinical trials for the treatment of liver cancer. Through its TCR discovery platform, the company is discovering novel targets and developing innovative therapies for unmet clinical needs. Recognising the need to address accessibility and scalability of immunotherapy, the company has also established a platform for autologous cell therapy and off-the-shelf therapy products.
About the CGT Asia Innovation Summit:
The Cell and Gene Therapy (CGT) Asia Innovation Summit aimed at providing strong support for the direction of cell and gene therapy research and transformation, promoting industry research and development capabilities, and enhancing brand influence. The nominees of the awards are evaluated by professionals based on technical practicality and innovation, market performance (market share, benchmark products/companies),customer evaluation (quality assurance, service process clarity), growth potential, and intellectual property. The organizer, Taas Labs, focuses on the latest developments in the Chinese and global biopharmaceutical industry, providing a platform for online and offline communication and information for different fields such as cell therapy, gene therapy, DNA/RNA therapy, and vaccines, accelerating the development of the Chinese biopharmaceutical industry and helping to create a global biopharmaceutical industry center.
Lion TCR Secures USD 40 million Series B2 Financing, Revolutionizing Solid Tumor Treatment with mRNA-Encoding TCR-T Cell Therapy
Lion TCR Clinched The "Outstanding Innovative Award" At The 2023 Cell And Gene Therapy (CGT) Asia Innovation Summit.
Lion TCR Announces Poster Presentation of Phase 1 Study for Lead Product LioCyx-M at AASLD The Liver Meeting 2022
Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma
Scientific Founder & Chairman, Professor Antonio Bertoletti Has Been Placed on Highly Cited Researchers 2021 List
Lion TCR Announces FDA Clearance of its IND Application for its Lead Investigational Product, LioCyx-M004, for Hepatocellular Carcinoma
Scientific Founder, Prof Antonio Bertoletti Appointed as Cellular Immunotherapy Infectious Diseases Lead for Singhealth Duke-NUS Cell Therapy Centre
Lion TCR Licenses and Duke-NUS Medical School ink an exclusive IP licensing agreement for Immunosuppressive Drug Resistant Anti-Cancer T-cells
Dr Wai Lu-En, Director of R&D, represented Lion TCR to share the latest developments to the Minister for Manpower and Second Minister for Trade and Industry Tan See Leng.
Scientific Founder, Prof Antonio Bertoletti Appointed in Cell and Gene Therapy Workgroup in Singapore
Lion TCR Announces Data Presentation for its lead T-cell product, LioCyx-M at EASL Digital Liver Cancer Summit 2021
HSA approval for clinical trial for Lion TCR’s lead product LioCyx-M to characterize changes in liver cancer tumor microenvironment
Lion TCR presents two abstracts of Phase 1 clinical trial data for lead product LioCyx-M at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Companion diagnostic assay for personalised immunotherapy for HBV-related liver cancer featured in A*STAR GIS website
Singapore’s first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer
Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
Scientific Founder, Prof. Antonio Bertoletti and Scientific Consultant, Dr Anthony Tanoto Tan of Lion TCR were awarded the SingHealth Duke-NUS Research Award 1st Prize 2018
US FDA grants Lion TCR two orphan drug designations of T cell therapy against Hepatocellular Carcinoma
Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient